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Two weeks’ isolation is widely recommended for people commencing treatment for pulmonary
tuberculosis (TB). The evidence that this corresponds to clearance of potentially infectious
tuberculous mycobacteria in sputum is not well established. This World Health Organization–
commissioned review investigated sputum sterilisation dynamics during TB treatment.
Methods and findings
For the main analysis, 2 systematic literature searches of OvidSP MEDLINE, Embase, and
Global Health, and EBSCO CINAHL Plus were conducted to identify studies with data on
TB infectiousness (all studies to search date, 1 December 2017) and all randomised con-
trolled trials (RCTs) for drug-susceptible TB (from 1 January 1990 to search date, 20 Febru-
ary 2018). Included articles reported on patients receiving effective treatment for culture-
confirmed drug-susceptible AU : Ichangeddrug   sensitivetodrug   susceptibletomatchusageintherestofthepaper:Ifthisisnotcorrect; pleaseedit:pulmonary TB. The outcome of interest was sputu bacterio-
logical conversion: the proportion of patients having converted by a defined time point or a
summary measure of time to conversion, assessed by smear or culture. Any study design
with 10 or more particpants AU : Hereitstatesthatstudiesincludingmorethan10participantsð> 10Þwereincluded:InTable1; itstatesthatstudieswithfewerthan10participantsð< 10Þwereexcluded:Thevalue10isnotincludedineitherofthesecategories:PleaseedithereorinTable1ifthecategoriesshouldbe < 10and � 10; or � 10and > 10; ratherthan < 10and > 10Þ:was considered. Record sifting a d data extraction were per-
formed in duplicate. Random effects meta-analyses were performed. A narrative summary
additionally describes the results of a systematic search for data evaluating infectiousness
from humans to experimental animals (PubMed, all studies to 27 March 2018). Other evi-
dence on duration of infectiousness—including studies reporting on cough dynamics,
human tuberculin skin test conversion, or early bactericidal activity of TB treatments—was
outside the scope of this review. The literature search was repeated on 22 November 2020,
at the request of the editors, to identify studies published after the previous censor date.
Four small studies reporting 3 different outcome measures were identified, which included
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no data that would alter the findings of the review; they are not included in the meta-analy-
ses. Of 5,290 identified records, 44 were included. Twenty-seven (61%) were RCTs and 17
(39%) were cohort studies. Thirteen studies (30%) reported data from Africa, 12 (27%) from
Asia, 6 (14%) from South America, 5 (11%) from North America, and 4 (9%) from Europe.
Four studies reported data from multiple continents. Summary estimates suggested smear
conversion in 9% of patients at 2 weeks (95% CI 3%–24%, 1 single study [N = 1]), and 82%
of patients at 2 months of treatment (95% CI 78%–86%, N = 10). Among baseline smear-
positive patients, solid culture conversion occurred by 2 weeks in 5% (95% CI 0%–14%, N =
2), increasing to 88% at 2 months (95% CI 84%–92%, N = 20). At equivalent time points, liq-
uid culture conversion was achieved in 3% (95% CI 1%–16%, N = 1) and 59% (95% CI
47%–70%, N = 8). Significant heterogeneity was observed. Further interrogation of the data
to explain this heterogeneity was limited by the lack of disaggregation of results, including
by factors such as HIV status, baseline smear status, and the presence or absence of lung
cavitation.
Conclusions
This systematic review found that most patients remained culture positive at 2 weeks of TB
treatment, challenging the view that individuals are not infectious after this interval. Culture
positivity is, however, only 1 component of infectiousness, with reduced cough frequency
and aerosol generation after TB treatment initiation likely to also be important. Studies that
integrate our findings with data on cough dynamics could provide a more complete perspec-
tive on potential transmission of Mycobacterium tuberculosis by individuals on treatment.
Trial registration
Systematic review registration: PROSPERO 85226.
Author summary
Why was this study done?
• Though cited in many countries’ national guidance, the evidence that individuals with
pulmonary tuberculosis (TB) are rendered non-infectious by 2 weeks of effective TB
treatment is challenged.
• This systematic review was commissioned by the World Health Organization to provide
evidence to inform TB infection prevention and control guidelines.
• We sought to synthesise the available data on the clearance of potentially infectious TB
bacteria from the sputum of patients after starting effective treatment.
What did the researchers do and find?
• We performed systematic searches of literature databases to identify relevant articles,
using predetermined inclusion criteria. Extracted data were synthesised using narrative
summaries and meta-analyses.
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Abbreviations: DS-TBAU : Pleasecheckthattheabbreviationsarecorrectlydefined:Ifyoumakeanyedits; pleasereplicatetheseeditseveryplacetheabbreviationsaredefinedinthepaperðabstract;maintext; andfigureandtablelegendsÞ:, drug-susc ptible
pulmonary tuberculosis; GDG, Guideline
Development Group; IPC, infection prevention and
control; MDR-TB, multi-drug-resistant
tuberculosis; Mtb, Mycobacterium tuberculosis;
PC, proportion converted; PTB, pulmonary
tuberculosis; RCT, randomised controlled trial; TB,
tuberculosis; TST, tuberculin skin test; TTC, time to
conversion; WHO, World Health Organization.
• A minority of patients had clearance of TB bacteria from sputum at 2 weeks of effective
treatment, as assessed by either sputum smear or culture.
• As expected, the proportion having cleared TB bacteria from sputum increased over
time; however, at 2 months of treatment 12% and 41% of patients still had viable TB bac-
teria present, as assessed by solid and liquid culture, respectively.
What do these findings mean?
• The presence of viable TB bacteria in the sputum of pulmonary TB patients beyond 2
weeks of effective treatment suggests individuals may be infectious for longer than this
interval.
• TB transmission requires the presence of viable mycobacteria in sputum and a mecha-
nism for aerosol or droplet spread. Understanding how other factors, such as the pres-
ence of cough, change during treatment is also important for TB infection prevention
and control.
Introduction
Tuberculosis (TB) is the leading cause of death from an infectious disease [1]. Mycobacterium
tuberculosis (Mtb), the causative organism, is transmitted via respiratory droplet nuclei gener-
ated by individuals with pulmonary TB (PTB). Transmission is affected by environmental fac-
tors, characteristics of both the source case and exposed individual, and the nature of their
contact. The greatest risk is from individuals with smear-positive PTB and high cough fre-
quency [2–4]. Interruption of transmission requires identification and separation of infectious
individuals until they are rendered non-infectious through treatment. Multiple countries’
national guidance documents recommend isolation of hospitalised individuals, with 2 weeks
of effective treatment commonly cited as the time frame after which patients are considered
non-infectious [5–9]. Implementing respiratory isolation has considerable resource implica-
tions, and is often unachievable in overstretched health systems in low- and middle-income
countries, where the greatest burden of TB lies [1].
The evidence base for the 2-week ‘rule’ has been repeatedly challenged by data demonstrat-
ing that most baseline sputum-culture-positive patients positive remain so for longer than 14
days [10]. These individuals are potentially infectious, although diminished cough frequency
may reduce transmission [4,11].
This systematic review was commissioned by the World Health Organization (WHO)
Department of Global TB Programme AU : IeditedthedepartmentnamefromWHOGlobalTBDepartmenttoWHODepartmentofGlobalTBProgrammepertheWHOwebsite : https : ==www:who:int=tb=about=en= : e : text ¼ The%20WHO%20Department%20of%20Global;Neglected%20Tropical%20Diseases%20ðHTMÞ:Ifthisisnotthecorrectofficialname; pleaseprovidecorrectname:Guideline Dev lopment Group (GDG) to synthesise
evidence on the dynamics of potential infectiousness of individuals with PTB receiving effec-
tive therapy, informing the 2019 guideline update on TB infection prevention and control
(IPC) [12].
Potential infectiousness was defined here as detection of Mtb by sputum smear or culture,
irrespective of cough dynamics or contact mixing patterns. Whilst smear microscopy may
detect non-viable, and therefore non-infectious, bacilli, it is referenced as a measure of treat-
ment response in published guidelines and in clinical practice. Molecular methods (Mtb DNA
detection, e.g., Xpert MTB/RIF [Cepheid]) also detect non-viable bacilli and are not routinely
used in assessment of treatment response; such assessments were excluded from this analysis.
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Two types of evidence were considered: (1) data on time from treatment initiation to spu-
tum smear and culture conversion and (2) data from measurements of infectiousness from
PTB patients to experimental animals. Although cough is clearly important, review of cough
dynamics during TB treatment did not form part of this study. Studies evaluating early bacteri-
cidal activity and human-to-human transmission were also considered outside the scope of
this study.
Methods
This review is reported following Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines [13]. Our PRISMA checklist is located in S1 PRISMA Check-
list. A prospectively registered review protocol is available in PROSPERO (https://www.crd.
york.ac.uk/PROSPERO, study ID 85226 [background question 3]).
Search strategy
A professional librarian developed and executed the literature search, in consultation with the
WHO GDG. The population of interest was patients receiving an effective treatment regimen
for drug-susceptible PTB (DS-TB); the outcome of interest was bacteriological conversion of
sputum. Effective treatment required at least rifampicin (R) and isoniazid (H) throughout, pyr-
azinamide (Z) for the 2-month intensive phase, and administration at least 5 days per week.
Inclusion of ethambutol (E) and streptomycin (S) was permitted but not essential. Regimens
including drugs not conventionally regarded as first-line, such as quinolones, were excluded
[14]. The outcome was defined as either the proportion of participants achieving bacteriologi-
cal (smear or culture) conversion from positive to negative by fixed time points during treat-
ment (proportion converted [PC]) or time to conversion (TTC) for the study population. As a
descriptive analysis, no intervention or comparator group was defined.
Full search parameters are detailed in S1 Table and S2 Table. The search was constructed in
OvidSP MEDLINE, adapted and run in OvidSP Embase; OvidSP Global Health; and EBSCO
CINAHL Plus. Searches used subject headings where available, and search terms in the title
and abstract. Combinations of terms were used to capture the concepts of infectiousness and
TB. Language was limited to English, Japanese, Chinese, Russian, French, Spanish, and Portu-
guese. On initial screening of search results, the authors noted the absence of several rando-
mised controlled trials (RCTs) known to include culture conversion data in standard
treatment arms. An additional search was therefore constructed identifying all RCTs of DS-TB
treatment in humans. The first search was conducted on 1 December 2017 without date
restrictions; the second (RCT search) was conducted on 20 February 2018, with date limited to
1990 onwards, to identify RCTs incorporating standard daily rifampicin-based regimens.
To mitigate the risk of overlooking important data reported since our search censor date,
during manuscript review we conducted a further literature search of OvidSP MEDLINE and
Embase on 22 November 2020. We used the original search terms (S1 Table and S2 Table)
combined with terms identified as being common either as keywords or in the titles/abstracts
of studies already included in the review. Full details, including additional search terms, are
provided in S1 Appendix.
Study selection and data extraction
Two-stage sifting AU : PleasecheckthattheeditstothesentenceTwo   stagesifting:::captureyourmeaning:Ifnot; pleaseprovidecorrectwording:by 2 ind pendent review rs was employed, applying pr de ermined eligibil-
ity criteria at title and abstract review and, where necessary, full-text screening. References and
citations for all included studies were reviewed to identify further relevant articles. Inclusion
and exclusion criteria are defined in Table 1.
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Data were extracted in duplicate into a standardised, pilot-tested Excel database (Microsoft
Office 2016) (S1 Form). As our intention was to analyse an ‘on treatment’ population, data
from per-protocol analyses were preferentially used. Data were not directly extracted from sys-
tematic reviews; instead, source papers were identified and reviewed for inclusion. At each
stage of screening and extraction, disagreements were resolved by a third independent
reviewer.
Quality assessment was performed by 2 independent reviewers at study level using an
adapted National Institutes of Health tool for case series [15].
Analysis
Extracted data were synthesised using a narrative approach, and meta-analyses where appro-
priate. TTC data were presented as study-specific estimates (mean or median) together with a
measure of spread (interquartile range, standard error, standard deviation, or range) where
provided.
Random effects meta-analyses were used to calculate pooled conversion proportions across
detection method subgroups (smear, solid culture, or liquid culture) at different time points.
Where the culture type was not stated, those performed prior to 1990 were assumed to use
solid media; others are reported as ‘unspecified’. Study-specific CIs were calculated using the
score method. Weighted pooled proportion estimates were calculated for each subgroup using
the Freeman–Tukey double arcsine transformation, avoiding potential bias introduced from
excluding studies with conversion proportions equalling 0 or 1 [16]. Pooled estimate CIs were
calculated using the Wald method. Within-subgroup heterogeneity was assessed with the chi-
Table 1. Summary of inclusion and exclusion criteria employed during record sifting.
Component Inclusion criteria Exclusion criteria
Participants • Bacteriologically confirmed (smear- or culture-positive) pulmonary
tuberculosis
• Confirmed drug susceptibility to, at least, rifampicin and isoniazida
• Treated with a regimen including rifampicin and isoniazid with
pyrazinamide added during 2-month ‘intensive phase’, administered at
least 5 days per weekb
• Any study not reporting data on participants with confirmed, drug-
susceptible pulmonary tuberculosis (or disaggregated data for this
subgroup)
• Any study not in humans
• Any study reporting on participants not treated with a conventional first-
line regimen [14] (e.g., addition of quinolones), or with treatment given
fewer than 5 days per weekb
Outcome
measures
Studies reporting data on at least 1 of the outcome measures of interest:
• Proportion of participants achieving sputum smear microscopy or
culture conversionc, assessed at any time point within the first 4 months
of treatment
• A summary measure (such as mean or median) of time to conversion,
assessed by repeated smear or culturec assessment (at any interval)
during treatment
• Any study not reporting on any of the outcomes of interest
Study types • Any consecutive case series, case–control study, cohort study,
randomised controlled study, systematic review, or meta-analysis
• Any systematic review superseded by an updated systematic review
• Narrative reviews not adding new data or new analysis of data to existing
knowledge
• Commentaries and mathematical modelling studies
• Studies with fewer than 10 participants per arm
• Any study not written in English, Japanese, Chinese, Russian, French,
Spanish, or Portuguese
• Any study published before 1946
aCriterion only applied at full-text review, as infrequently reported in abstracts.
bWhere studies used an included regimen for an initial period, with an excluded regimen later (e.g., during continuation phase, or insufficient duration of
pyrazinamide), the study was included and data extracted only for the period where an included regimen was administered.
cSputum smear and culture assessment could be by any method including Ziehl–Neelsen stain, fluorescence microscopy, liquid or solid culture, or an undefined culture
method.
https://doi.org/10.1371/journal.pmed.1003566.t001
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squared test and described with the I2 statistic. Data cleaning was conducted in Stata (Stata/IC
version 13.1), and meta-analyses performed in R (R Core Team, 2020) using the ‘forest.meta’
function from the package ‘meta’ [17].
Animal studies
A review of data on Mtb transmission from humans to animals was explicitly requested by the
WHO GDG and was undertaken as a separate search and analysis. The population of interest
was patients receiving effective treatment for drug-susceptible or drug-resistant PTB. The out-
come of interest was transmission to experimental animals exposed to air exhausted from iso-
lation facilities accommodating TB patients, defined as tuberculin skin test (TST) conversion
or new active TB disease in these animals.
The search was run on 27 March 2018; details are provided in S3 Table. Titles and abstracts,
then full texts of identified papers were reviewed. References and citations of included papers
were also reviewed. The diversity and heterogeneity of methodologies and analyses applied by
included studies did not permit standardised data extraction or quality assessment. Relevant
data were extracted for narrative synthesis by 1 reviewer and independently checked for accu-
racy by a second.
Results
In total, 5,290 unique records were identified for title and abstract review (first search: 3,558;
RCT search: 1,732). Full-text review of 180 papers identified 22 studies for inclusion in the
main analysis. A further 22 articles were added from references and citations (Fig 1), resulting
in 44 papers for analysis (Table 2).
The further literature search conducted in November 2020 identified 4 small studies meet-
ing the inclusion criteria, each with under 150 participants and reporting 3 different outcome
measures [18–21]. The results reported in these studies did not address any of the data gaps in
important subgroups and had no material impact upon the results or conclusions of this
review so were not incorporated into the meta-analyses. Further details of the eligible studies
are provided in Table B in S1 Appendix.
Of the included papers, 27 (61%) were RCTs and 17 (39%) were cohort studies (Table 2).
Thirteen studies (30%) reported data from Africa, 12 (27%) from Asia, 6 (14%) from South
America, 5 (11%) from North America, and 4 (9%) from Europe. Four studies reported data
from multiple continents. Intensive phase treatment in most studies comprised RHZE (31
studies), 6 studies used streptomycin instead of ethambutol, and the remainder used other
acceptable regimens (RHZ with or without E or S). Seventeen studies included people living
with HIV, representing between 0.8% and 61% of the study population. Thirty-three studies
only included people with baseline smear-positive PTB.
Eight studies reported both PC and TTC data, 31 studies reported only PC data, and 5
reported only TTC data. For data on the proportion of patients achieving bacteriological conver-
sion, there were a total of 96 estimates: 4, 5, and 6 estimates at 1, 2, and 3 weeks of treatment,
respectively, and 20, 46, 7, and 8 estimates at 1, 2, 3, and 4 months, respectively (Table 3).
Thirty-seven studies were ranked as ‘good’ in the quality scoring system (�7/9)AU : gooddefinitioneditedfrom > 7=9to � 7=9; perS4Table:Ifthisisnotcorrect; pleaseprovidecorrectdefinition:, with 7
studies ranked as ‘fair’ (4–6/9), and none as ‘poor’ quality (S4 Table).
Smear conversion
Fifteen studies reporting data on smear conversion were included, providing 18 estimates of
the proportion of individuals who had smear converted at defined time points on treatment
and 6 summary estimates of the time to smear conversion.
PLOS MEDICINE Sputum conversion during tuberculosis treatment
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For the 6 studies reporting a summary estimate of time to smear conversion, the median
TTC ranged from 20 to 27 days and the mean TTC ranged from 29 to 55 days (Table 4).
Shorter times to conversion were seen in studies with more frequent sampling.
The proportions of treated patients with baseline smear-positive DS-TB achieving positive-
to-negative smear conversion are shown in Fig 2. From a total of 18 estimates across 11 studies,
the proportions of baseline smear-positive patients achieving smear conversion at the 1-, 2-,
3-, and 4-month time points were 33% (95% CI 25%–42%), 82% (95% CI 78%–86%), 94%
(95% CI 94%–95%), and 100% (95% CI 72%–100%), respectively.
Culture conversion
Thirty-seven studies reported data on culture conversion. Ten studies published after 1990 did
not report the culture method and were excluded from the main analysis (TTC and PC data
with meta-analysis are reported in S5 Table and S1 Fig, respectively.).
Among studies with data on culture method, 10 used liquid culture, 25 used solid, and 8
used both. Summary statistics for TTC were reported in 11 studies. These are summarised by
Fig 1. Flow diagram showing databases searched and process for article inclusion. AU : ThereisanasteriskintheAdditionalrecordsincludedboxinFig1; butnocorrespondingfootnoteinthelegendforFig1:Pleaseeitherð1Þdeletetheasteriskorð2Þprovidethemissingfootnoteinformationinthefigurelegend:Two searches wer developed, conducted by a
professional librarian: a primary search and a second search that aimed to identify all RCTs of tuberculosis treatment conducted since
1990, as described in text. DSTB, drug-susceptible tuberculosis; n, number of studies; RCT, randomised controlled trial.
https://doi.org/10.1371/journal.pmed.1003566.g001
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Table 2. Description of included studies.
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Table 2. (Continued)
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culture medium in Table 5. All 6 studies reporting solid TTC data included only smear-posi-
tive patients at baseline. The median TTC ranged from 35 to 49 days, and the mean TTC ran-
ged from 24 to 46 days.
Four studies reported a summary estimate of liquid TTC. Median TTC ranged from 40 to
59 days among baseline smear-positive patients. One study stratified liquid culture TTC by
smear status, with a median TTC of 19 days in baseline smear-negative patients compared to
40 days for smear-positive patients.
Table 2. (Continued)




















Lee [59] 2014 South
Korea















54 (±21) 36% <1% 2RHZ±
S/E¶��AU : IsthereanumbermissingfromtheintensivetreatmentcellforLeung½60� : � RHZ?Greaterorequaltowhat?
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BMRC, AU : IeditedtheabbreviationslistforTable2tomatchPLOSstyle;andaddedafewmissingabbreviations:Pleasecheckthattheabbreviationdefinitionsarecorrect:British Medical Resea ch Council; BTA, British Thoracic Associa ion; C, cohort study (p, prospective; r, re r spective); C+, ulture-positive subgroup; DOT,
directly observed therapy (values in parentheses indicate duration); E, ethambutol; ECA, East and Central African; FM, fluorescence microscopy; H, isoniazid; HIV−,
people living without HIV; HIV+, people living with HIV; HKCS, Hong Kong Chest Service; IP, hospital inpatient; NS, not specified; PC, proportion converted; R,
rifampicin; RCT, randomised controlled trial; S, streptomycin; S+, smear-positive subgroup; S. Am., South America; SSA, sub-Saharan Africa; STBS, Singapore
Tuberculosis Service; Smoker−, without smoking exposure; Smoker+, with smoking exposure; TB, tuberculosis; TBRC, Tuberculosis Research Centre; TTC, time to
conversion; U-INH, urine isoniazid metabolite testing; Z, pyrazinamide; ZN, Ziehl–Neelsen;—, data not available.
�Number assessed for outcome. Where demographics were not given for the population assessed for outcome, number in brackets indicates the number for which
demographics were stated (which may include drug-resistant TB, non-RHZ-containing regimens, etc.). Where available, per-protocol or efficacy analyses were
extracted.
†Age is given as median (interquartile range) or mean (± standard deviation) unless otherwise stated.
‡In the treatment abbreviations, the number indicates the number of months of treatment, and letters indicate the drugs included. TreatmentAU : PleasecheckthatthesentenceIaddedtothe z footnoteexplainingthetreatmentabbreviationsiscorrect:Ifnot;pleaseprovidecorrectexplanation:given 7 d ys per week
unless otherwise stated (5 d = 5 days per week).
§For studies performed before 1990, culture type assumed to be solid unless otherwise stated.
¶Paper stated treatment was in accordance with national or international guidelines; corresponding regimen shown here. In all other papers, drugs used were explicitly
stated.
||Individuals not adherent to DOT (as defined by authors) excluded from analysis.
��It is not possible to exclude that some patients were treated with thrice-weekly regimens in these studies.
††These studies used the same dataset and overlapping time frames; however, the estimates presented are different. They therefore contribute to different analyses. Two
further papers that included overlapping data were excluded to avoid duplication [66,67].
‡‡Includes a proportion of patients with unknown HIV status.
§§Percentage of study population receiving DOT.
https://doi.org/10.1371/journal.pmed.1003566.t002
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The proportions of treated patients with DS-TB achieving positive-to-negative culture con-
version at weeks 1, 2, and 3 and months 1, 2, 3, and 4 (77 estimates in total) are shown in Fig 3
and Fig 4 for solid and liquid culture methods, respectively.
Most PC data are available at the 2-month time point, where treatment steps down from
intensive to maintenance phase. Fig 5 illustrates the proportion of patients achieving culture
conversion at 2 weeks and 2 months, restricted to only patients with baseline smear-positive
samples.
The proportion of patients treated for DS-TB achieving smear and culture conversion at
each time point is summarised in Table 6.
Animal studies
The search to identify relevant animal studies returned 646 results, from which 3 were found
to be relevant at title and abstract sifting; all met inclusion criteria at full-text sifting. A fourth
study (Riley et al. [68]) was added from reference and citation checking of the included articles
(Fig 6; Table 7).
These 4 papers all describe experimental data from studies in which groups of guinea pigs,
used as air samplers, were exposed to air exhausted from dedicated isolation rooms accommo-
dating PTB patients. Three studies evaluated the infectiousness from patients with DS-TB [68–
70] to experimental animals, and 1 study considered patients with multi-drug-resistant TB
(MDR-TB) [71]. None of the experiments were designed to evaluate temporal changes in
Table 3. Number of estimates contributing to proportion converted analysis by time point and microbiological assessment method.
Duration of treatment Smear Culture Total
Solid Liquid Not specified
1 week 0 4 0 0 4
2 weeks 1 3 1 0 5
3 weeks 1 3 1 1 6
1 month 4 12 2 2 20
2 months 10 23 9 4 46
3 months 1 3 1 2 7
4 months 1 5 1 1 8
Total 18 53 15 10 96
https://doi.org/10.1371/journal.pmed.1003566.t003
Table 4. Studies reporting a summary measure of time to smear conversion�AU : PleasechecktheeditstothecolumnheadsinTable4forcorrectness:.
Study Year Country N Sampling frequency Smear stain Median TTC, days Mean TTC, days TTC spread (measure)
Kennedy [45] 1996 Tanzania 81 Monthly FM — 55 30–120 (range)
Dominguez-Castellano [31] 2003 Spain 95 Weekly ZN 20 — ±2 (SE)
Telzak [56] 1997 US 77 Weekly ZN — 33 ±6.2 (SE)
Long [46] 2003 Canada 32 Daily to day 14 then 2×/week† FM — 46 ±27.9 (SD)
Rathored [49] 2012 India 50 Weekly ZN — 29 ±0.7 (SD)
Méchaï [47] 2016 France 30 2×/week‡ NS 27 — 14–56 (IQR)
FM, fluorescence microscopy; IQR, interquartile range; N, number assessed for outcome; NS, not stated; SD, standard deviation; SE, standard error; TTC, time to
conversion; ZN, Ziehl–Neelsen.
�Where authors reported data in months, these have been converted to days to aid comparisons (using 30.4 days per month).
†For 14 prospectively studied patients; for 18 retrospectively studied patients sampling was weekly (mean of 1.6 per week) throughout treatment.
‡On days 7–9 then on 3 days every 2 weeks.
https://doi.org/10.1371/journal.pmed.1003566.t004
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infectiousness during TB treatment; however, Dharmadhikari et al. re-analysed 5 previous
experiments with this objective [71]. As such, the available data are opportunistically available
and incomplete, and it is not possible to determine the magnitude of incompleteness. Due to
considerable methodological and analytical differences between studies, aggregation of find-
ings was not possible. A brief narrative summary of each individual paper is provided in S2
Appendix.
Overall, the 3 papers evaluating infectiousness of air from patients with DS-TB suggested
that those on treatment were less infectious to guinea pigs than untreated patients, although a
small number of infections did occur during effective treatment. There are no data that
describe how infectiousness changed over time after treatment initiation. It was not possible to
Fig 2. Proportion of patients with baseline smear-positive, drug-susceptible tuberculosis achieving smear conversion at specified time points during
effective treatment. BMRC, British Medical Research Council; CI, confidence interval; ECA, East and Central African.
https://doi.org/10.1371/journal.pmed.1003566.g002
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disaggregate guinea pig infections occurring from patients with drug-resistant TB on or off
effective treatment in the paper by Dharmadhikari et al. It is not possible from these data to
draw conclusions about the role of effective treatment in reducing infectiveness of TB, nor
about the time frame over which any reduction in infectiousness occurs.
Discussion
This systematic review and these meta-analyses show that after 2 weeks of effective treatment,
95% and 97% of baseline smear-positive patients demonstrated persistently positive solid and
liquid cultures, respectively. This directly challenges guidance that IPC measures can be
relaxed following 2 weeks of effective treatment. Despite an effective drug regimen for DS-TB,
approximately 1 in 5 baseline smear-positive patients did not achieve smear conversion by 2
months of treatment, decreasing to 1 in 20 by 3 months. It is important for clinicians and pro-
grammes to appreciate this significant tail of individuals who, despite receiving effective ther-
apy, remain smear positive. On completion of the 2-month intensive treatment phase, 12%
and 41% of baseline smear-positive patients remained solid and liquid culture positive,
respectively.
Identification of people with active TB and initiation of effective treatment are vital compo-
nents of TB IPC, mediated through what is conventionally perceived as a rapid reduction in
the infectiousness of treated patients. As part of the evidence gathering for the 2019 WHO
guidelines on TB IPC [12], we undertook this systematic review and meta-analysis to investi-
gate the dynamics of sputum sterilisation after initiation of effective treatment.
To our knowledge, this is the first systematic review drawing together the data on the
dynamics of sputum sterilisation during effective TB treatment. Strengths of this study include
a comprehensive search strategy identifying a large number of studies. We were careful to
ensure that all individuals included in the review were receiving an effective drug regimen to
avoid confounding by ineffective treatment, and included several outcome assessment meth-
ods. A further literature search performed prior to publication did not identify any significant
new bodies of work addressing conversion dynamics, or studies that would significantly
impact the findings of this review.
The core of this analysis relates to culture conversion as this is an assessment of the presence
of viable Mtb in respiratory samples. We included data on smear conversion as the most
Table 5. Studies reporting a summary measure of time to solid or liquid culture conversion�AU : ThemeasureofspreadgivenformeanTTCwaslabeledSDinbothcases; soIdeletedSEfromthecolumnheadandabbreviationslist:Pleaseconfirmthatthisiscorrect:.
Study Year Country Smear+ Sampling frequency Solid culture Liquid culture




N Median TTC, days
(IQR)
Conde [24] 2009 Brazil 100% Weekly 72 49 — — —
Rathored [49] 2012 India 100% Every 2 weeks 50 — 24 ± 0.7 — —
Lee [59] 2014 South Korea 100% Monthly after 2
weeks
— — — 61 40 (28–61)
0% 101 19 (1–41)





100% Weekly 54 35 — 56 56
Dawson [28]
(2015b)
2015 South Africa 100% Weekly 36 43 (29–52) 46 ± 27.9 38 59 (36–63)
Conde [25] 2016 Brazil 100% Weekly 45 41 (35–48) — 36 52 (41–59)
N, number assessed for outcome; IQR, interquartile range; SD, standard deviation; TTC, time to conversion;—, data not available.
�Where authors reported data in months, these have been converted to days to aid comparisons (using 30.4 days per month).
https://doi.org/10.1371/journal.pmed.1003566.t005
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frequently used microbiological test used for response to therapy; however, smear positivity of
treated patients may not reflect presence of viable Mtb. The evaluation of TB transmission
from human patients to experimental animals provides an additional perspective.
Whilst presence of Mtb in respiratory secretions is a necessary component of infectiousness,
assessment of the capacity to detect Mtb in spontaneously produced sputum does not directly
quantify infectiousness. Infectiousness also depends on the environment, a mechanism for
propagation (e.g., cough dynamics), and recipient factors. This is a limitation of this review
Fig 3. Proportion of baseline culture-positive patients receiving effective treatment for drug-susceptible
tuberculosis achieving solid culture conversion at specified time points. BMRC, British Medical Research Council;
BTA, British Thoracic Association; CI, confidence interval; HKCS, Hong Kong Chest Service; STBS, Singapore
Tuberculosis Service; T, Tanzania; TBRC, Tuberculosis Research Centre.
https://doi.org/10.1371/journal.pmed.1003566.g003
Fig 4. Proportion of baseline culture-positive patients receiving effective treatment for drug-susceptible tuberculosis achieving liquid culture conversion at
specified time points. CI, confidence interval.
https://doi.org/10.1371/journal.pmed.1003566.g004
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Fig 5. Proportion of baseline smear-positive patients receiving effective treatment for drug-susceptible tuberculosis, achieving solid culture and liquid
culture conversion at 2 weeks and 2 months. BMRC, British Medical Research Council; CI, confidence interval; ECA, East and Central African; HKCS, Hong
Kong Chest Service; STBS, Singapore Tuberculosis Service; T, Tanzania.
https://doi.org/10.1371/journal.pmed.1003566.g005
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with regard to public health policy. Cough frequency diminishes significantly in the first few
weeks of effective TB treatment. This likely plays an important role in reducing transmission
risk, but was outside the scope of this review [4,11]. We also excluded studies reporting human
TST conversion, which could provide a ‘real world’ assessment of infectiousness. To our
knowledge, however, there are no studies reporting TST conversion rates attributable to spe-
cific time points or time periods following treatment initiation. We also did not include quan-
titative evaluations of sputum mycobacterial load after treatment initiation, for example from
studies of early bactericidal activity. Declining sputum mycobacterial load after initiation of
treatment could provide evidence for declining infectiousness; however, without culture con-
version, the time at which an individual becomes non-infectious cannot be determined.
Another limitation for the interpretation of the presented estimates is the high level of
observed heterogeneity between studies, resulting in a lack of precision in the presented esti-
mates. This is a consequence of the diverse patient populations sampled across a high number
of included studies. There is no ‘typical’ TB cohort. Patients vary widely in terms of sexAU : Shouldgenderðsociallyconstructedcharacteristicsofwomenandmen suchasnorms; roles; andrelationshipsÞbesexðbiologicallymaleversusfemaleÞinstead?Ifso; pleasechange:, age,
exposure history, disease duration and severity (including smear status and presence or
absence of lung cavitation), Mtb strain lineage, nutritional status, profile of comorbidities such
as HIV and diabetes, and tolerance of and adherence to treatment. Many of these covariates
are independently associated with time to sputum conversion [31,56]. ThisAU : PleasecheckthattheeditstothesentenceThisleadsto:::captureyourmeaning:Ifnot; pleaseprovidecorrectwording:leads to importan
variation in time to culture conversion between individuals, which is magnified by aggregation
of patients into study populations. Where possible we conducted subgroup analyses to explore
observed heterogeneity; however, few studies disaggregated results by key covariates, and het-
erogeneity remained high, even within subgroups.
In our analyses, we found that liquid culture remained positive for longer than solid culture
and that smears assessed by fluorescence microscopy staining were positive for longer than
those assessed by Ziehl–Neelsen staining. This is unsurprising, given liquid culture and fluo-
rescence microscopy staining are considered more sensitive detection methods [72,73]. How-
ever, observed differences may also reflect imbalances in confounding covariates across
subgroups. Lack of disaggregation by conversion-predicting covariates such as HIV status,
baseline smear status, and the presence of cavitating lung disease prevented any meaningful
Table 6. Overview of summary estimates derived from random effects meta-analysis for the proportion of patients achieving culture conversion at each time point,
by detection method.








1 week — 0 — 0.01
(0.00–0.03)











































CI, confidence interval; N, number of estimates.
https://doi.org/10.1371/journal.pmed.1003566.t006
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attempt to explore potential confounding. Point estimates of TTC are expected to be influ-
enced by the frequency of sampling; however, this parameter was often not reported. These
limitations should be recognised when inferring a relationship between detection method and
conversion estimates.
The proportion of estimated new cases successfully treated for MDR-TB globally was 55%
at the time of this work [1]. The scope of the review was therefore restricted to patients with
proven DS-TB in an effort to ensure all included patients were receiving effective treatment.
Fig 6. Flow diagram showing process of identification of animal studies for review. n, number of studies.
https://doi.org/10.1371/journal.pmed.1003566.g006
Table 7. Studies evaluated for data on infectiousness from TB patients to animals during TB treatment.
Study Year Drug susceptibility of population Untreated patients (N or percent) Treated patients (N or percent) Treatment duration
Riley [68] 1962 DS 67 40 Not clear
Escombe [69] 2007 Mixed� 17% of patient-days 83% of patient-days Not clear
Escombe [70] 2008 Mixed� Not clear
Dharmadhikari [71] 2014 MDR/XDR Variable (across 5 studies) Not clear
DS, drug-susceptible; MDR, multi-drug-resistant; N, number assessed; XDR, extensively drug-resistant.
�Included AU : Ichangeddrug   sensitivetodrug   susceptibletomatchusageintherestofthepaper:Ifthisisnotcorrect;pleaseedit:individuals with g-susc ptible TB and those with drug-resistant TB.
https://doi.org/10.1371/journal.pmed.1003566.t007
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Our findings are therefore not generalisable to MDR-TB. The restriction of the review to
DS-TB also resulted in the exclusion of many articles, including all search results reported only
in abstract form, because drug susceptibility testing was not performed or not reported, or
because conversion estimates were not disaggregated by drug susceptibility testing results.
Adherence is critical to effective treatment. Many studies reported using directly observed
therapy and some included other mechanisms for adherence support, but very few reported
adherence data. The possibility of incomplete adherence further limits the interpretation of
our findings. Consequently, our analyses should be considered analogous to an intention-to-
treat rather than an on-treatment protocol.
Beyond the indirect measure of sputum conversion time alone, we sought to explore when
TB treatment renders patients non-infectious by reviewing studies using experimental animals
as air samplers. In these studies, air extracted from isolation rooms housing TB patients is
exhausted over susceptible guinea pigs, exposing them to infectious droplet nuclei. Modifica-
tion of patient conditions, including the use of effective treatment, can be exploited to infer the
effect of interventions on infectiousness, assessed by serial tuberculin skin testing of exposed
animals. These studies suggest that patients receiving effective TB treatment were less infec-
tious than those not receiving such treatment; however, the temporal dynamics of infectious-
ness could not be elicited from the identified studies, individually or when combined.
This systematic review was performed to inform the WHO Department of Global TB Pro-
gramme GDGAU : Departmentnameeditedhereasabove:Ifthisisnotthecorrectofficialname; pleaseprovidecorrectname:of the evidenc available to answer the ques ion ‘How does the infectiousness of
TB patients (ability to excrete viable bacteria and sustain transmission) change after having
started effective TB treatment?’ Our summary estimates of culture conversion suggest that the
majority of patients excrete viable bacilli at 2 weeks of treatment, and many continue to do so
for several months. What this AU : IeditedWhatthismeansthe2   weekruletoWhatthismeansforthe2   weekrule:Ifthisdoesnotcaptureyourmeaning; pleaseeditasnecessary:means for the 2-week ‘rule’ cannot be determined by thes anal-
yses, as we did not evaluate other factors that are also important for TB transmission. These
are important gaps to address for evidence-based TB IPC guidance. Integrating the findings of
this review with data on cough dynamics, the impact of environmental factors such as air
changes per hour, and varying host susceptibility through a modelling approach could provide
a more comprehensive assessment of TB transmission during treatment. Studies of TST con-
versions of experimental animals, with the objective of evaluating transmission dynamics after
TB treatment initiation, would also provide new insight.
Viable Mtb persists in sputum for months after initiation of TB treatment. Understanding
the implications of this for TB transmission from patients on treatment necessitates a compre-
hensive evaluation including not only the persistence of Mtb in sputum, but also the contribu-
tion of other host and pathogen factors, including cough dynamics.
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